Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948 | 0.64 | — | — | |
| SCHEMBL29539 | 0.64 | — | — | |
| SCHEMBL1289715 | 0.64 | — | — | |
| SCHEMBL19678 | 0.62 | — | — | |
| SCHEMBL20528826 | 0.62 | TRPA1 (0.34) | PARP1 | |
| SCHEMBL37705 | 0.62 | PNMT (0.39) | HTR2C | |
| SCHEMBL28776095 | 0.62 | — | — | |
| SCHEMBL8343541 | 0.62 | TRPA1 (0.34) | PARP1 | |
| SCHEMBL19579719 | 0.60 | HTR2C (0.48) | PARP1HTR2C | |
| SCHEMBL155336 | 0.60 | PARP1 (0.39) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070189970-A1 | Contrast medium for thrombus formation | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | US | claimed |
| EP-1719529-A1 | CONTRAST MEDIUM FOR THROMBUS FORMATION | Astellas Pharma Inc. (JP) | 2006-11-08 | — | — | EP | claimed |
| EP-2404899-A1 | Contrast medium for thrombus detection | Astellas Pharma Inc. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20070189970-A1 | Contrast medium for thrombus formation | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719529-A1 | CONTRAST MEDIUM FOR THROMBUS FORMATION | Astellas Pharma Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070189970-A1 | Contrast medium for thrombus formation | FGB, F13B, TFPI | PARP1 4239/4885HTR2C 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.